Statines in pregnancy
Until a few years ago, the classification of the Food and Drug Administration (FDA) to indicate the level of risk of drugs on the fetus established five categories (A, B, C, D, X). Category X included contraindicated drugs, among which were statins. That is to say, there was a formal contraindicatio...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Sello Editorial Lugones
2022-09-01
|
| Series: | Revista de la Sociedad Argentina de Diabetes |
| Subjects: | |
| Online Access: | https://revistasad.com/index.php/diabetes/article/view/607 |
| Summary: | Until a few years ago, the classification of the Food and Drug Administration (FDA) to indicate the level of risk of drugs on the fetus established five categories (A, B, C, D, X). Category X included contraindicated drugs, among which were statins. That is to say, there was a formal contraindication for statins to be used during pregnancy, or in women who could become pregnant, due to their possible teratogenic effects. Studies published after this categorization provided new data on the subject. In particular, they question the positive association between the use of statins in the embryogenic period and congenital malformations. Some studies have even shown that intrauterine exposure to statins favors prematurity and/or low birth weight. |
|---|---|
| ISSN: | 0325-5247 2346-9420 |